←Back to Expert Scholars
Translational Medicine / 转化医学RNAseq Profiling, Breast Cancer
Laura van't Veer
PhD
🏢UCSF Helen Diller Family Comprehensive Cancer Center🌐USA
Professor, Leader Breast Oncology Program
95
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Laura van't Veer developed the 70-gene MammaPrint breast cancer prognostic signature, validated in the MINDACT trial. She leads the breast oncology program at UCSF. Her work established genomic risk stratification as a tool to guide adjuvant chemotherapy decisions.
Share:
🧪Research Fields 研究领域
MammaPrint
70-gene signature
MINDACT
breast cancer genomics
precision adjuvant
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Laura van't Veer 的研究动态
Follow Laura van't Veer's research updates
留下邮箱，当我们发布与 Laura van't Veer（UCSF Helen Diller Family Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment